secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celcuity Inc. (CELC)
CIK:        0001603454
Form:       8-K
Filed at:   2022-09-14T23:59:59+00:00
Accession:  0001493152-22-025891
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 3.03, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celcuity appoints Dr. Polly Murphy to Board; reduces warrant shares to 70K
--------------------------------------------------------------------------

- Warrant amended: shares reduced from 138,000 to 70,000; exercise period extended to Sept 19, 2025.
- Board expanded to 7 directors; Dr. Polly Murphy elected as independent director, effective immediately.
- Dr. Murphy brings 20+ years of pharma biz dev experience including 12 years at Pfizer; currently CBO of UroGen Pharma.
- Dr. Murphy granted options: 16,300 shares vesting by 2023 annual meeting or April 30, 2023; plus 10,000 shares vesting over 4 years.
- Company expects to dose first patient in Phase 3 gedatolisib study for HR+/HER2- breast cancer in next few months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1603454/000149315222025891/0001493152-22-025891-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1603454/000149315222025891/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-025891

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer